Dr. Jonathan Harry Schatz, MD

Dr. Schatz practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Schatz's NPI, 1285880021, was assigned on August 12, 2008. Dr. Schatz graduated from Pritzker School of Medicine in 2004. Dr. Schatz's New York license number on file is 243865-1.

Dr. Schatz's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Schatz's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System. Dmand AI also links Dr. Schatz to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schatz practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Schatz's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Schatz is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Schatz's licenses on file in 3 states: New York, Florida and Arizona.

Dmand AI lists chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Schatz treats.

CMS data shows 140 Medicare services from Dr. Schatz across 2 procedure codes in 2024, for 57 Medicare patients. Medicare paid $11,306 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 57 Medicare patients who saw Dr. Schatz in 2024. The largest group is 75 to 84, with 27 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 28% are also on Medicaid. Their average risk score is 2.75, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schatz's median patient age at 72, with 44% women.

In 2024, Dr. Schatz wrote 174 Medicare Part D claims for 21 patients. 75% of them were for generic drugs. CMS names the drug for 100 of them, across 5 drugs with 11 or more claims each, at $395,173 in total drug cost. In 2023, CMS named 72 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Schatz for performance year 2024, reported as part of a group. Dr. Schatz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schatz as offering telehealth.

Dmand AI links 58 papers to Dr. Schatz, published from 2010 to 2025. 2021 was the busiest year, with 5. The most frequent topics are Cell Line, Tumor, Lymphoma, Large B-Cell, Diffuse and Antineoplastic Agents. Dr. Schatz has published most often in Blood. Dr. Schatz's most frequent co-authors are Asaad Trabolsi, MD, Soham Puvvada, MD and Francisco Vega, MD.

CMS Open Payments shows 62 general payments to Dr. Schatz from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 85% of the total. Acrotech Biopharma LLC paid the most, $7,732.

Dmand AI lists 5 awards for Dr. Schatz, most recently Mortimer J. Lacher Fellowship in 2009.

Dr. Schatz graduated from Pritzker School of Medicine in 2004.

Dr. Schatz is in network with 10 carriers, including Elevance, Aetna and United Healthcare. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.